story of the week
Atezolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Lancet Oncol 2023 Dec 12;[EPub Ahead of Print], E Grande, JÁ Arranz, M De Santis, A Bamias, E Kikuchi, XG Del Muro, SH Park, U De Giorgi, B Alekseev, M Mencinger, K Izumi, FA Schutz, J Puente, JR Li, PH O'Donnell, AR Kalebasty, D Ye, S Mariathasan, F Bene-Tchaleu, S Bernhard, C Lee, ID Davis, MD GalskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.